Trials / Unknown
UnknownNCT05310123
AC-11 Supplement and Biological Aging
Investigation of AC-11® Supplementation in Reversing Epigenetic Markers of Biological Aging Including Those Related to Telomere Length
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 32 (estimated)
- Sponsor
- TruDiagnostic · Industry
- Sex
- All
- Age
- 55 Years
- Healthy volunteers
- Accepted
Summary
This is a prospective non-randomized clinical study of 24 patients to evaluate the effects of the AC-11®. The study will evaluate the effectiveness of the supplement's ability to reverse epigenetic markers of biological age. The duration of the study will be 6 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | AC-11 | 6-months of treatment with AC-11 |
Timeline
- Start date
- 2021-05-26
- Primary completion
- 2022-10-01
- Completion
- 2022-10-01
- First posted
- 2022-04-04
- Last updated
- 2022-04-11
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT05310123. Inclusion in this directory is not an endorsement.